BridgeBio Pharma Gestione
Criteri Gestione verificati 4/4
BridgeBio Pharma Il CEO è Neil Kumar, nominato in Apr2015, e ha un mandato di 11.25 anni. la retribuzione annua totale è $ 14.94M, composta da 7% di stipendio e 93% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.59% delle azioni della società, per un valore di $ 391.93M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.2 anni e 6.5 anni.
Informazioni chiave
Neil Kumar
Amministratore delegato
US$14.9m
Compenso totale
| Percentuale dello stipendio del CEO | 6.99% |
| Mandato del CEO | 11.3yrs |
| Proprietà del CEO | 2.6% |
| Durata media del management | 5.2yrs |
| Durata media del Consiglio di amministrazione | 6.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Jun 29
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish
Summary BridgeBio Pharma, Inc. remains a Buy, driven by Attruby's commercial launch and a robust late-stage pipeline targeting rare genetic diseases. BBIO's $14bn+ valuation is underpinned by four potential blockbuster drugs by 2030, with key NDA catalysts in 2026–2027. Attruby faces future competitive and formulary pressures as Vyndaqel generics and Vyndamax patent expiry approach, yet management asserts superior efficacy. A $500m share buyback and strong clinical execution support optimism, but narrowing losses and successful FDA approvals are critical for upside. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Jun 22
BBIO: ATTR Cardiomyopathy Rollout And Rare Disease NDA Milestones Will Reprice Shares
BridgeBio Pharma's updated analyst price target framework reflects a modestly higher fair value estimate of about $136, as analysts factor in mixed Street revisions that incorporate recent Q1 model updates, new coverage tied to Attruby and the rare disease pipeline, and differing views on payer risks and the recent regulatory milestones. Analyst Commentary Street commentary on BridgeBio Pharma currently reflects a mix of enthusiasm around Attruby, the rare disease portfolio, and key regulatory updates, offset by caution around payer dynamics and how these factors could influence valuation over time.
Aggiornamento della narrazione • Jun 05
BBIO: Priority Review Rare Disease Pipeline Will Drive Post 2026 Upside
Analysts raised their blended fair value estimate for BridgeBio Pharma by about $1.82 to roughly $102.71, citing fresh price targets around $98 to $104, growing confidence in the Attruby launch, the broader rare disease pipeline, and added visibility from BBP-418's FDA Priority Review. Analyst Commentary Street research on BridgeBio Pharma is mixed, with several firms adjusting price targets and ratings around the Attruby launch, pipeline milestones, and regulatory updates such as the Priority Review for BBP-418.
Aggiornamento della narrazione • May 20
BBIO: Cardiomyopathy Launch And Late Stage Filings Will Drive Next Phase
BridgeBio Pharma's fair value estimate has been trimmed by $4 to $76 as analysts balance a higher discount rate and more measured revenue growth against ongoing support for Attruby and the broader pipeline, as reflected in recent price target updates across the Street. Analyst Commentary Street research on BridgeBio continues to cluster around Attruby execution, valuation upside tied to pipeline milestones, and the impact of tafamidis settlement dynamics.Aggiornamento della narrazione • May 01
BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside
Analysts have inched their average price target for BridgeBio higher, with fair value estimates moving from about $100.61 to $100.89 as they factor in updated views on Attruby traction, achondroplasia data, and the potential impact of recent settlement headlines with large pharma peers. Analyst Commentary Street research on BridgeBio has been active, with price targets and fair value estimates moving as analysts update their views on Attruby uptake, achondroplasia data, and the implications of recent settlement headlines with large pharmaceutical peers.Aggiornamento della narrazione • Apr 17
BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence
Analysts have nudged their fair value target for BridgeBio Pharma higher, from $100.05 to $100.61, citing stronger assumptions around Attruby traction, a wider late stage pipeline, and updated P/E expectations reflected in recent price target hikes across several firms. Analyst Commentary Street research around BridgeBio has been active, with several firms updating models after Q4 Attruby data, infigratinib readouts and fresh coverage initiations.Aggiornamento della narrazione • Apr 03
BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares
Analysts slightly raised their average price target on BridgeBio Pharma to $132.57 per share, citing updated models that factor in recent Attruby sales trends, positive infigratinib achondroplasia data, and the company’s progress toward becoming a multi-product commercial business. Analyst Commentary Bullish analysts have been steadily lifting their price targets on BridgeBio Pharma in recent months, reflecting updated views on valuation that incorporate Attruby sales, late stage pipeline progress, and the company’s push toward a broader commercial footprint.Aggiornamento della narrazione • Mar 20
BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares
The updated analyst price target for BridgeBio Pharma moves to $132.57, reflecting analysts' focus on stronger fair value assumptions, a slightly lower discount rate, and higher projected profit margins supported by recent research pointing to Attruby's momentum and late stage pipeline progress. Analyst Commentary Recent Street research points to a cluster of bullish analysts revisiting their models on BridgeBio Pharma, with several lifting fair value estimates and highlighting execution around Attruby and the late stage pipeline.Aggiornamento della narrazione • Mar 05
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026
The analyst fair value estimate for BridgeBio Pharma has increased from $89.79 to $100.05, reflecting a series of upward revisions to Street price targets as analysts factor in stronger Attruby sales trends and progress across the broader late-stage pipeline. Analyst Commentary Recent research updates cluster around two main themes for BridgeBio Pharma: valuation support from Attruby, and expectations for the broader late stage pipeline.Aggiornamento della narrazione • Feb 19
BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase
The analyst price target for BridgeBio Pharma has been reset from $41 to $80, with analysts citing recent price target increases across the Street and positive Phase 3 PROPEL 3 achondroplasia data as key supports for the higher fair value view. Analyst Commentary Recent Street research has pointed to higher price targets for BridgeBio Pharma following the Phase 3 PROPEL 3 readout and updated views on the company’s late stage pipeline.Aggiornamento della narrazione • Feb 05
BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing
Analysts have lifted their price targets on BridgeBio Pharma, supporting a higher implied fair value of about $128 per share as they factor in updated models, a strengthened view of the company’s late stage pipeline and expectations for its genetic disease portfolio. Analyst Commentary Bullish analysts are leaning into a higher fair value framework for BridgeBio, updating models around the genetic disease portfolio and later stage programs.Aggiornamento della narrazione • Jan 22
BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026
Analysts have lifted their fair value estimate for BridgeBio Pharma to about $89.79 from roughly $84.65, citing higher modeled revenue growth and profit margins, along with updated expectations for the late stage pipeline and therapies such as Attruby, encaleret and BBP-418. Analyst Commentary Recent research updates highlight a generally constructive stance on BridgeBio Pharma, with multiple firms revising price targets and pointing to the late stage pipeline and commercial traction of key assets as central to their views.Aggiornamento della narrazione • Jan 07
BBIO: Late-Stage Genetic Programs Are Expected To Drive Bullish Repricing
Analysts have trimmed their fair value estimate for BridgeBio Pharma slightly to about $108.70 per share from $109.61. This reflects updated views on higher projected revenue growth, a wider profit margin profile, and a lower assumed future P/E multiple informed by recent positive readouts and pipeline driven price target increases across the Street.Aggiornamento della narrazione • Dec 24
BBIO: Late-Stage Pipeline Progress Will Drive Bullish Repricing Ahead
BridgeBio Pharma's analyst price target has been raised meaningfully, with fair value estimates climbing from approximately $88 to $110 as analysts factor in stronger visibility on late stage programs like Attruby, infigratinib, encaleret, and BBP-418. These programs collectively de risk the pipeline and support higher long term profitability.Aggiornamento della narrazione • Dec 10
BBIO: Late Stage Pipeline Progress Will Drive Confidence Into 2026 And Beyond
Analysts nudged their average price target for BridgeBio Pharma up by about $1 to roughly $84.65 per share, citing stronger than expected Attruby revenue traction, rising conviction in BBP-418 and encaleret Phase 3 success, and greater visibility on multiple late stage catalysts into 2026. Analyst Commentary Bullish analysts are largely aligned on a constructive outlook for BridgeBio, emphasizing upside to current revenue forecasts, increasing confidence in late stage programs, and a clearer path to market for several key assets.Aggiornamento della narrazione • Nov 26
BBIO: Positive Regulatory Momentum Will Drive Confidence Ahead Of 2026 Approvals
BridgeBio Pharma's analyst price target has been raised slightly, increasing from $83.11 to $83.65. Analysts cite positive clinical updates, higher probability of regulatory approvals, and stronger than expected revenue performance as key drivers for the upward revision.Aggiornamento della narrazione • Nov 10
BBIO: Positive Late-Stage Data Will Drive Confidence Ahead Of 2026 Regulatory Decisions
BridgeBio Pharma's analyst price target has been raised significantly, from approximately $66 to over $83. Analysts cite stronger-than-expected revenue, promising pipeline data, and increased confidence in future product approvals as key drivers for the upward revision.Aggiornamento della narrazione • Oct 27
Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion
BridgeBio Pharma's analyst price target has been revised upward, with the average fair value increasing modestly from $66.32 to $66.47. Analysts highlight strong early commercial momentum, underappreciated pipeline opportunities, and rising revenue estimates for key assets.Aggiornamento della narrazione • Oct 13
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts have raised their price targets on BridgeBio Pharma by as much as $10 to $82 per share. They cite better-than-expected drug uptake, upcoming clinical milestones, and upgraded sales projections as justification for their increased optimism.Aggiornamento della narrazione • Sep 29
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target was revised upward, driven by stronger-than-expected commercial uptake of Acoramidis (Attruby), upwardly revised peak sales estimates for key assets, and de-risked late-stage pipeline catalysts, resulting in a new price target of $66.32 from $65.10. Analyst Commentary Bullish analysts cite strong commercial momentum and better-than-expected uptake of Acoramidis (Attruby), particularly in transthyretin amyloid cardiomyopathy (ATTR-CM), as driving upward revisions to price targets.Aggiornamento della narrazione • Sep 14
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
BridgeBio Pharma’s consensus price target has been raised to $65.10, driven by increasing analyst confidence in its pipeline progress—particularly for ADH1 and BBP-418, ongoing strong sales momentum for Attruby in ATTR-CM, and multiple upcoming catalysts—reflecting a notably improved valuation outlook. Analyst Commentary Bullish analysts are confident in Phase 3 data readouts for pipeline assets, particularly autosomal dominant hypocalcemia type 1 (ADH1) and limb-girdle muscular dystrophy type 2I/R9 (BBP-418), viewing them as underappreciated and meaningful opportunities likely to expand BridgeBio’s addressable market.Aggiornamento della narrazione • Aug 30
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.Nuova narrazione • Aug 10
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins.Articolo di analisi • Aug 09
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
NasdaqGS:BBIO 1 Year Share Price vs Fair Value Explore BridgeBio Pharma's Fair Values from the Community and select...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$722m |
| Dec 31 2025 | US$15m | US$1m | -US$725m |
| Sep 30 2025 | n/a | n/a | -US$797m |
| Jun 30 2025 | n/a | n/a | -US$776m |
| Mar 31 2025 | n/a | n/a | -US$668m |
| Dec 31 2024 | US$16m | US$988k | -US$536m |
| Sep 30 2024 | n/a | n/a | -US$439m |
| Jun 30 2024 | n/a | n/a | -US$454m |
| Mar 31 2024 | n/a | n/a | -US$538m |
| Dec 31 2023 | US$12m | US$742k | -US$643m |
| Sep 30 2023 | n/a | n/a | -US$613m |
| Jun 30 2023 | n/a | n/a | -US$573m |
| Mar 31 2023 | n/a | n/a | -US$425m |
| Dec 31 2022 | US$7m | US$1m | -US$481m |
| Sep 30 2022 | n/a | n/a | -US$491m |
| Jun 30 2022 | n/a | n/a | -US$509m |
| Mar 31 2022 | n/a | n/a | -US$596m |
| Dec 31 2021 | US$26m | US$725k | -US$563m |
| Sep 30 2021 | n/a | n/a | -US$535m |
| Jun 30 2021 | n/a | n/a | -US$495m |
| Mar 31 2021 | n/a | n/a | -US$520m |
| Dec 31 2020 | US$10m | US$550k | -US$449m |
| Sep 30 2020 | n/a | n/a | -US$402m |
| Jun 30 2020 | n/a | n/a | -US$346m |
| Mar 31 2020 | n/a | n/a | -US$291m |
| Dec 31 2019 | US$26m | US$503k | -US$261m |
Compensazione vs Mercato: La retribuzione totale di Neil ($USD 14.94M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.46M ).
Compensazione vs guadagni: La retribuzione di Neil è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Neil Kumar (47 yo)
11.3yrs
Mandato
US$14,944,585
Compensazione
Dr. Neil Kumar, Ph D., is Executive Chairman of BridgeBio Oncology Therapeutics, Inc. from April 20, 2026. He serves as an Independent Director at Maze Therapeutics, Inc. since March 27, 2026.He has been...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$14.94m | 2.59% $ 391.9m | |
| CFO & President | 2yrs | US$5.83m | 0.18% $ 27.7m | |
| Co-Founder | no data | US$1.12m | 0.47% $ 70.4m | |
| Co-Founder | no data | US$1.10m | 0.39% $ 58.6m | |
| Chief Accounting Officer | 3.5yrs | Nessun dato | 0.066% $ 10.0m | |
| Chief Scientific Officer | 10.3yrs | US$2.75m | Nessun dato | |
| Chairman of Research & Development | 7.5yrs | US$2.01m | Nessun dato | |
| Chief Scientific Officer of Oncology | 6.6yrs | Nessun dato | Nessun dato | |
| Chief Executive Officer of Gene Therapy | no data | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 5.2yrs | Nessun dato | Nessun dato | |
| Chief Regulatory Affairs Officer | 4.5yrs | Nessun dato | Nessun dato | |
| President & Chief Medical Officer of Cardiovascular and Renal Diseases | 4.3yrs | Nessun dato | Nessun dato |
5.2yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di BBIO è esperto e expertise (durata media dell'incarico 5.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$14.94m | 2.59% $ 391.9m | |
| Co-Founder | 7.7yrs | US$1.12m | 0.47% $ 70.4m | |
| Co-Founder | 3.4yrs | US$1.10m | 0.39% $ 58.6m | |
| Lead Independent Director | 4.9yrs | US$599.95k | 0.011% $ 1.7m | |
| Independent Director | 6.4yrs | US$599.95k | 0.0064% $ 972.1k | |
| Independent Director | 7.3yrs | US$599.95k | 0.0011% $ 169.3k | |
| Independent Director | 10.3yrs | US$599.95k | 0.083% $ 12.5m | |
| Independent Director | 10.3yrs | US$599.95k | 0.046% $ 7.0m | |
| Independent Director | 6.6yrs | US$599.95k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$649.95k | 0.031% $ 4.7m | |
| Independent Director | 4.9yrs | US$599.95k | 0.011% $ 1.7m | |
| Independent Director | 4.9yrs | US$599.95k | 0.0073% $ 1.1m |
6.5yrs
Durata media
63yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BBIO sono considerati esperti (durata media dell'incarico 6.5 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/05 04:02 |
| Prezzo dell'azione a fine giornata | 2026/07/02 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
BridgeBio Pharma, Inc. è coperta da 36 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Eliana Merle | Barclays |
| William Pickering | Bernstein |
| Jason Zemansky | BofA Global Research |